Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma

References

• Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10:230-52; PMID:23604045; http://dx.doi.org/10.1038/cmi.2013.10
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui C-H, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-9; PMID:20085940; http://dx.doi.org/10.1200/JCO.2009.24.4590
   PubMed Web of Science ®Google Scholar
• Klingemann HG. Cellular therapy of cancer with natural killer cells-where do we stand? Cytotherapy 2013; 15:1185-94; PMID:23768925; http://dx.doi.org/10.1016/j.jcyt.2013.03.011
   PubMed Web of Science ®Google Scholar
• Koehl U, Sörensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33:261-6; PMID:15528141; http://dx.doi.org/10.1016/j.bcmd.2004.08.013
   PubMed Web of Science ®Google Scholar
• Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 2004; 6:15-22; PMID:14985163; http://dx.doi.org/10.1080/14653240310004548
   PubMed Web of Science ®Google Scholar
• Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11:341-55; PMID:19308771; http://dx.doi.org/10.1080/14653240902807034
   PubMed Web of Science ®Google Scholar
• Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 2015; 17:621-32; PMID:25881519; http://dx.doi.org/10.1016/j.jcyt.2015.03.611
   PubMed Web of Science ®Google Scholar
• Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program 2013; 2013:234-46; PMID:24319186; http://dx.doi.org/10.1182/asheducation-2013.1.234
   PubMed Web of Science ®Google Scholar
• Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012; 7:e30264; PMID:22279576; http://dx.doi.org/10.1371/journal.pone.0030264
   PubMed Web of Science ®Google Scholar
• Parrish-novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408:57-63; PMID:11081504; http://dx.doi.org/10.1038/35040504
   PubMed Web of Science ®Google Scholar
• Davis MR, Zhu Z, Hansen DM, Bai Q, Fang Y. The role of IL-21 in immunity and cancer. Cancer Lett 2015; 358:107-14; PMID:25575696; http://dx.doi.org/10.1016/j.canlet.2014.12.047
   PubMed Web of Science ®Google Scholar
• Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: A mediator of the transition from innate to adaptive immunity. Immunity 2002; 16:559-69; PMID:11970879; http://dx.doi.org/10.1016/S1074-7613(02)00295-9
   PubMed Web of Science ®Google Scholar
• Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004; 172:2048-58; PMID:14764669; http://dx.doi.org/10.4049/jimmunol.172.4.2048
   PubMed Web of Science ®Google Scholar
• Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007; 122:486-95; PMID:17635612; http://dx.doi.org/10.1111/j.1365-2567.2007.02675.x
   PubMed Web of Science ®Google Scholar
• Strbo N, de Armas L, Liu H, Kolber MA, Lichtenheld M, Pahwa S. IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS 2008; 22:1551-60; PMID:18670213; http://dx.doi.org/10.1097/QAD.0b013e3283089367
   PubMed Web of Science ®Google Scholar
• Lim DP, Jang YY, Kim S, Koh SS, Lee JJ, Kim JS, Thi Phan MT, Shin DJ, Shin MG, Lee SH et al. Effect of exposure to interleukin-21 at various time points on human natural killer cell culture. Cytotherapy 2014; 16:1419-30; PMID:24950680; http://dx.doi.org/10.1016/j.jcyt.2014.04.008
   PubMed Web of Science ®Google Scholar
• Li Q, Ye L-J, Ren H-L, Huyan T, Li J, Shi J-L, Huang Q-S. Multiple effects of IL-21 on human NK cells in ex vivo expansion. Immunobiology 2015; 220:876-88; PMID:25758713; http://dx.doi.org/10.1016/j.imbio.2015.01.009
   PubMed Web of Science ®Google Scholar
• Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res 2014; 20:3390-400; PMID:24987108; http://dx.doi.org/10.1158/1078-0432.CCR-13-1766
   PubMed Web of Science ®Google Scholar
• Tam YK, Miyagawa B, Ho VC, Klingemann HG. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8:281-90; PMID:10417052; http://dx.doi.org/10.1089/106161299320316
   PubMedGoogle Scholar
• Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10:625-32; PMID:18836917; http://dx.doi.org/10.1080/14653240802301872
   PubMed Web of Science ®Google Scholar
• Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov 2015; 14:487-98; PMID:26000725; http://dx.doi.org/10.1038/nrd4506
   PubMed Web of Science ®Google Scholar
• Ni J, Miller M, Stojanovic A, Cerwenka A. Toward the next generation of NK cell-based adoptive cancer immunotherapy. Oncoimmunology 2013; 2:e23811; PMID:23734329; http://dx.doi.org/10.4161/onci.23811
   PubMedGoogle Scholar
• Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother 2015; 38:24-36; PMID:25415285; http://dx.doi.org/10.1097/CJI.0000000000000059
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Cursinger J, McKenna D et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13:98-107; PMID:20849361; http://dx.doi.org/10.3109/14653249.2010.515582
   PubMed Web of Science ®Google Scholar
• Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant 2014; 20:1252-7; PMID:24816582; http://dx.doi.org/10.1016/j.bbmt.2014.05.004
   PubMed Web of Science ®Google Scholar
• Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11:1238-43; PMID:16227988; http://dx.doi.org/10.1038/nm1312
   PubMed Web of Science ®Google Scholar
• Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010; 59:1739-44; PMID:20680271; http://dx.doi.org/10.1007/s00262-010-0896-z
   PubMed Web of Science ®Google Scholar
• Nayar S, Dasgupta P, Galustian C. Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies–A review. Oncoimmunology 2015; 4:e1002720; PMID:26155387; http://dx.doi.org/10.1080/2162402X.2014.1002720
   PubMedGoogle Scholar
• Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology 2014; 3:e28147; PMID:25340009; http://dx.doi.org/10.4161/onci.28147
   PubMed Web of Science ®Google Scholar
• Salagianni M, Baxevanis CN, Papamichail M, Perez SA. New insights into the role of NK cells in cancer immunotherapy. Oncoimmunology 2012; 1:205-7; PMID:22720243; http://dx.doi.org/10.4161/onci.1.2.18398
   PubMed Web of Science ®Google Scholar
• Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824
   PubMed Web of Science ®Google Scholar
• Zhang B, Karrison T, Rowley DA. Schreiber H. IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118:1398-404; PMID:18317595; http://dx.doi.org/10.1172/JCI33522
   PubMed Web of Science ®Google Scholar
• Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012; 209:2351-65; PMID:23209317; http://dx.doi.org/10.1084/jem.20120944
   PubMed Web of Science ®Google Scholar